138 related articles for article (PubMed ID: 27585122)
21. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.
Tomita Y; Karapetis CS; Ullah S; Townsend AR; Roder D; Beeke C; Roy AC; Padbury R; Price TJ
Acta Oncol; 2016; 55(4):480-5. PubMed ID: 26878155
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
24. Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
Shitara K; Matsuo K; Kondo C; Takahari D; Ura T; Inaba Y; Yamaura H; Sato Y; Kato M; Kanemitsu Y; Komori K; Ishiguro S; Sano T; Shimizu Y; Muro K
Oncology; 2011; 81(3-4):167-74. PubMed ID: 22057124
[TBL] [Abstract][Full Text] [Related]
25. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
[TBL] [Abstract][Full Text] [Related]
26. Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.
Padman S; Padbury R; Beeke C; Karapetis CS; Bishnoi S; Townsend AR; Maddern G; Price TJ
Acta Oncol; 2013 Nov; 52(8):1699-706. PubMed ID: 24102180
[TBL] [Abstract][Full Text] [Related]
27. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of the primary tumor’s nodal status after surgery for colorectal liver metastases in the era of effective systemic therapy.
van der Stok EP; Grünhagen DJ; Alberda WJ; Reitsma M; Rothbarth J; Verhoef C
Dig Surg; 2015; 32(3):208-16. PubMed ID: 25896431
[TBL] [Abstract][Full Text] [Related]
29. A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer.
Kumar R; Jain K; Beeke C; Price TJ; Townsend AR; Padbury R; Roder D; Young GP; Richards A; Karapetis CS
Cancer; 2013 Feb; 119(4):722-8. PubMed ID: 22990939
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.
John SK; Robinson SM; Rehman S; Harrison B; Vallance A; French JJ; Jaques BC; Charnley RM; Manas DM; White SA
Dig Surg; 2013; 30(4-6):293-301. PubMed ID: 23969407
[TBL] [Abstract][Full Text] [Related]
31. Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?
Reddy SK; Tsung A; Marsh JW; Geller DA
J Surg Oncol; 2012 Jan; 105(1):55-9. PubMed ID: 21842519
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic analysis of patients with liver metastases from colorectal cancer treated with different modes of therapy].
Fang H; Wang XY; Feng FY; Wang JW
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):67-70. PubMed ID: 20211074
[TBL] [Abstract][Full Text] [Related]
33. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution.
Ammori JB; Kemeny NE; Fong Y; Cercek A; Dematteo RP; Allen PJ; Kingham TP; Gonen M; Paty PB; Jarnagin WR; D'Angelica MI
Ann Surg Oncol; 2013 Sep; 20(9):2901-7. PubMed ID: 23771246
[TBL] [Abstract][Full Text] [Related]
34. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
Ferrarotto R; Pathak P; Maru D; Agarwal A; Overman M; Hoff PM; Kopetz S
Clin Colorectal Cancer; 2011 Sep; 10(3):178-82. PubMed ID: 21855039
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly patients with metastatic colorectal cancer: a single institution comparative study.
Bakogeorgos M; Mountzios G; Kotsantis G; Economopoulou P; Fytrakis N; Kentepozidis N
J BUON; 2013; 18(3):629-34. PubMed ID: 24065475
[TBL] [Abstract][Full Text] [Related]
37. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
Venderbosch S; Doornebal J; Teerenstra S; Lemmens W; Punt CJ; Koopman M
Acta Oncol; 2012 Sep; 51(7):831-9. PubMed ID: 22794910
[TBL] [Abstract][Full Text] [Related]
38. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
39. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
40. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study.
Ruers TJ; Joosten JJ; Wiering B; Langenhoff BS; Dekker HM; Wobbes T; Oyen WJ; Krabbe PF; Punt CJ
Ann Surg Oncol; 2007 Mar; 14(3):1161-9. PubMed ID: 17195903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
